All In Biotech

Drug Trial Radar · NCT07905157

A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants

A Phase 1, Randomized, Open-Label, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics and Safety of Bepirovirsen When Delivered From a Vial or a 1ml Autoinjector in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Nov 3, 2026

Primary completion

Mar 30, 2027

Study completion Mar 30, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label study being done to compare two different methods of study medicine bepirovirsen is given in healthy adults. The researchers want to learn how the body affects the medicine over time (pharmacokinetic \[PK\] study). The study will also evaluate the safety of bepirovirsen and how well it is tolerated, meaning how people feel after receiving the medicine and whether they experience any side effects.

Conditions

  • Hepatitis B

Interventions

  • BepirovirsenDrug

    Bepirovirsen will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-time Curve from Time Zero (pre-dose) up to Day 8 [AUC(0- 8 d)] of Bepirovirsen in PlasmaTime frame: Pre-dose to Day 8 (168 hours) post dose
  2. Maximum Observed Concentration (Cmax) of Bepirovirsen in plasmaTime frame: Pre-dose to Day 8 (168 hours) post dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.